Quantumzyme Corp. (OTC: QTZM), a biotransformation company specializing in enzyme-based solutions for pharmaceutical manufacturing, announced today that it plans to attend the 2026 BIO International Convention, scheduled for June 22–25, 2026, in San Diego, California. The company’s representatives will focus on observation and informal networking rather than exhibiting or presenting, as part of its ongoing efforts to engage with the biotechnology ecosystem.
The BIO International Convention is a premier global event gathering biotechnology and life sciences companies, academic institutions, and industry professionals across various scientific and commercial disciplines. Quantumzyme’s attendance underscores its commitment to staying abreast of industry developments and fostering dialogue with potential collaborators, technology partners, and stakeholders. The company will not be presenting, exhibiting, sponsoring, or formally participating in conference programming, limiting its involvement to listening and learning.
Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., emphasized the importance of the event: “We view the BIO International Convention as an important opportunity to connect with peers across the biotechnology and biomanufacturing ecosystem. Our attendance is focused on listening, learning, and engaging in informal discussions with industry participants as we continue to evaluate developments relevant to our technology and long-term objectives.”
This strategic approach aligns with Quantumzyme’s mission to advance sustainable enzyme-based solutions for pharmaceutical manufacturing. The company specializes in green chemistry, applying quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts that enhance efficiency, reduce waste, and support environmentally responsible production. By integrating computational modeling with laboratory validation, Quantumzyme aims to deliver scalable, cost-effective biocatalysis solutions that improve industrial sustainability.
Quantumzyme’s attendance at the BIO International Convention is part of its broader strategy to increase industry awareness and maintain dialogue with key players. However, the company cautions that there can be no assurance that discussions initiated during the conference will result in any agreements, transactions, or future business relationships. This announcement reflects the company’s deliberate, observational approach to exploring potential opportunities within the biomanufacturing sector.
For additional information about the BIO International Convention, visit https://convention.bio.org. More details about Quantumzyme Corp. can be found at www.quantumzymecorp.com and the company’s profile on www.otcmarkets.com/stock/QTZM.
